<?xml version="1.0" encoding="UTF-8"?><mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" ID="id-2026-16508">
    <name type="corporate">
        <namePart>United States Government Publishing Office</namePart>
        <role>
            <roleTerm authority="marcrelator" type="text">publisher</roleTerm>
            <roleTerm authority="marcrelator" type="code">pbl</roleTerm>
        </role>
        <role>
            <roleTerm authority="marcrelator" type="text">distributor</roleTerm>
            <roleTerm authority="marcrelator" type="code">dst</roleTerm>
        </role>
    </name>
    <name type="corporate">
        <namePart>United States</namePart>
        <namePart>National Archives and Records Administration</namePart>
        <namePart>Office of the Federal Register</namePart>
        <role>
            <roleTerm authority="marcrelator" type="text">author</roleTerm>
            <roleTerm authority="marcrelator" type="code">aut</roleTerm>
        </role>
        <description>Government Organization</description>
    </name>
    <typeOfResource>text</typeOfResource>
    <genre authority="marcgt">government publication</genre>
    <language>
        <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
    </language>
    <extension>
        <collectionCode>FR</collectionCode>
        <category>Regulatory Information</category>
        <waisDatabaseName>2026_register</waisDatabaseName>
        <branch>executive</branch>
        <dateIngested>2026-08-13</dateIngested>
    </extension>
    <genre authority="marcgt">article</genre>
    <titleInfo>
        <title>Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children</title>
        <partNumber>Part II</partNumber>
        <partName>Rules and Regulations</partName>
    </titleInfo>
    <relatedItem type="otherFormat" xlink:href="https://www.govinfo.gov/content/pkg/FR-2026-08-13/html/2026-16508.htm">
        <identifier type="FDsys Unique ID">D09002ee1e6b6c2a6</identifier>
    </relatedItem>
    <relatedItem type="otherFormat" xlink:href="https://www.govinfo.gov/content/pkg/FR-2026-08-13/pdf/2026-16508.pdf">
        <identifier type="FDsys Unique ID">D09002ee1e6b6c97d</identifier>
    </relatedItem>
    <name type="corporate">
        <namePart>United States</namePart>
        <namePart>Department of Health and Human Services</namePart>
        <role>
            <roleTerm authority="marcrelator" type="text">originator</roleTerm>
            <roleTerm authority="marcrelator" type="code">org</roleTerm>
        </role>
        <description>United States Government Agency or Subagency</description>
    </name>
    <name type="corporate">
        <namePart>United States</namePart>
        <namePart>Centers for Medicare &amp; Medicaid Services</namePart>
        <role>
            <roleTerm authority="marcrelator" type="text">originator</roleTerm>
            <roleTerm authority="marcrelator" type="code">org</roleTerm>
        </role>
        <description>United States Government Agency or Subagency</description>
    </name>
    <abstract>This final rule requires that a State Medicaid plan must provide that the Medicaid agency will not make payment under the plan for sex-rejecting procedures for children under 18, and prohibits the use of Federal Medicaid dollars to fund sex-rejecting procedures for individuals under the age of 18. In addition, this final rule requires that a separate State Children's Health Insurance Program (CHIP) plan must provide that the CHIP agency will not make payment under the plan for sex-rejecting procedures for children under 19, and prohibits the use of Federal CHIP dollars to fund sex-rejecting procedures for individuals under the age of 19. For Medicaid and CHIP beneficiaries who are actively receiving cross-sex hormone therapy, State Medicaid and CHIP agencies may continue to claim Federal Financial Participation for those hormone therapy medications for a period of up to 6 months from the effective date of this final rule.</abstract>
    <identifier type="FR citation">91 FR 52406</identifier>
    <identifier type="uri">https://www.govinfo.gov/app/details/FR-2026-08-13/2026-16508</identifier>
    <identifier type="FR Doc No.">2026-16508</identifier>
    <identifier type="former granule identifier">fr13au26-13</identifier>
    <identifier type="Regulation ID Number">RIN 0938-AV73</identifier>
    <identifier type="billing code">4169-69-P</identifier>
    <identifier type="department code">CMS-2451-F</identifier>
    <location>
        <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/FR-2026-08-13/2026-16508</url>
        <url access="raw object" displayLabel="HTML rendition">https://www.govinfo.gov/content/pkg/FR-2026-08-13/html/2026-16508.htm</url>
        <url access="raw object" displayLabel="PDF rendition">https://www.govinfo.gov/content/pkg/FR-2026-08-13/pdf/2026-16508.pdf</url>
    </location>
    <subject>
        <topic>Grant Programs-Healt</topic>
        <topic>Health Professions</topic>
        <topic>Medicaid</topic>
        <topic>Reporting and Recordkeeping Requirements</topic>
        <topic>Chip</topic>
        <topic>Grant Programs-Health</topic>
    </subject>
    <physicalDescription>
        <extent>69 p.</extent>
    </physicalDescription>
    <part type="Part II">
        <extent unit="pages">
            <start>52406</start>
            <end>52474</end>
        </extent>
    </part>
    <identifier type="preferred citation">91 FR 52406</identifier>
    <relatedItem type="isReferencedBy">
        <titleInfo>
            <title>Code of Federal Regulations</title>
            <partNumber>Title 42 Part 441</partNumber>
        </titleInfo>
        <identifier type="CFR citation">42 CFR Part  441</identifier>
    </relatedItem>
    <relatedItem type="isReferencedBy">
        <titleInfo>
            <title>Code of Federal Regulations</title>
            <partNumber>Title 42 Part 457</partNumber>
        </titleInfo>
        <identifier type="CFR citation">42 CFR Part  457</identifier>
    </relatedItem>
    <relatedItem type="isReferencedBy">
        <titleInfo>
            <title>Regulation Identification Number 0938-AV73</title>
        </titleInfo>
        <identifier type="regulation ID number">RIN 0938-AV73</identifier>
    </relatedItem>
    <extension>
        <searchTitle>Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children; Federal Register Vol. 91, Issue </searchTitle>
        <granuleClass>RULE</granuleClass>
        <accessId>2026-16508</accessId>
        <partNumber>II</partNumber>
        <agency order="1">DEPARTMENT OF HEALTH AND HUMAN SERVICES</agency>
        <agency order="2">Centers for Medicare &amp; Medicaid Services</agency>
        <effectiveDate>2026-10-13</effectiveDate>
        <departmentDoc>CMS-2451-F</departmentDoc>
        <rin number="0938-AV73"/>
        <billingCode>4169-69-P</billingCode>
        <frDocNumber>2026-16508</frDocNumber>
        <action>Final rule.</action>
        <summary>This final rule requires that a State Medicaid plan must provide that the Medicaid agency will not make payment under the plan for sex-rejecting procedures for children under 18, and prohibits the use of Federal Medicaid dollars to fund sex-rejecting procedures for individuals under the age of 18. In addition, this final rule requires that a separate State Children's Health Insurance Program (CHIP) plan must provide that the CHIP agency will not make payment under the plan for sex-rejecting procedures for children under 19, and prohibits the use of Federal CHIP dollars to fund sex-rejecting procedures for individuals under the age of 19. For Medicaid and CHIP beneficiaries who are actively receiving cross-sex hormone therapy, State Medicaid and CHIP agencies may continue to claim Federal Financial Participation for those hormone therapy medications for a period of up to 6 months from the effective date of this final rule.</summary>
        <dates>These regulations are effective on October 13, 2026.</dates>
        <contact>MedicaidSRPInquiries@cms.hhs.gov.</contact>
        <cfr title="42">
                                    
            <part number="441"/>
                                    
            <subject>Grant Programs-Healt</subject>
                                    
            <subject>Health Professions</subject>
                                    
            <subject>Medicaid</subject>
                                    
            <subject>Reporting and Recordkeeping Requirements</subject>
                                
        </cfr>
        <cfr title="42">
                                    
            <part number="457"/>
                                    
            <subject>Chip</subject>
                                    
            <subject>Grant Programs-Health</subject>
                                
        </cfr>
        <tocSubject1>Medicaid Program</tocSubject1>
        <tocDoc>Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children, </tocDoc>
        <emailRef>MedicaidSRPInquiries@cms.hhs.gov</emailRef>
        <urlRef>doi.org/10.1542/peds.2018-2162</urlRef>
        <urlRef>http://www.sba.gov/content/small-business-size-standards</urlRef>
        <urlRef>https://advocacy.sba.gov/wp-content/uploads/2025/07/Comment-Letter_Advocacy-Comments-to-HHS-Deregulatory-RFI.pdf</urlRef>
        <urlRef>https://aspe.hhs.gov/hhs-information-quality-peer-review</urlRef>
        <urlRef>https://aspe.hhs.gov/sites/default/files/documents/dd6288d1b8db19ee8a1f37b3ce775003/guidance-proper-consideration-hhs-2003-rulemaking.pdf</urlRef>
        <urlRef>https://aspe.hhs.gov/topics/data/information-quality-guidelines</urlRef>
        <urlRef>https://book.gradepro.org</urlRef>
        <urlRef>https://cass.independent-review.uk/home/publications/final-report/</urlRef>
        <urlRef>https://cass.independent-review.uk/wp-content/uploads/2022/09/20220726_Evidence-review_Gender-affirming-hormones_For-upload_Final.pdf</urlRef>
        <urlRef>https://cass.independent-review.uk/wp-content/uploads/2022/09/20220726_Evidence-review_GnRH-analogues_For-upload_Final.pdf</urlRef>
        <urlRef>https://cloud.e.ama-assn.org/newsletter</urlRef>
        <urlRef>https://dictionary.cambridge.org/us/dictionary/english/medicalization</urlRef>
        <urlRef>https://doi.org/10.1016/0022-5193</urlRef>
        <urlRef>https://doi.org/10.1016/j.tree.2011.12.006</urlRef>
        <urlRef>https://doi.org/10.1080/26895269.2022.2100644</urlRef>
        <urlRef>https://doi.org/10.1111/apa.16791</urlRef>
        <urlRef>https://doi.org/10.1136/bmj.o2303</urlRef>
        <urlRef>https://doi.org/10.1186/s12874-025-02581-7</urlRef>
        <urlRef>https://doi.org/10.1210/jc.2017-01658</urlRef>
        <urlRef>https://doi.org/10.1530/eje.1.02231</urlRef>
        <urlRef>https://doi.org/10.3390/jcm13226658</urlRef>
        <urlRef>https://doi.org/10.6065/apem.2040220.110</urlRef>
        <urlRef>https://icd.who.int/en/</urlRef>
        <urlRef>https://le.utah.gov/AgencyRP/reportingDetail.jsp?rid=636</urlRef>
        <urlRef>https://manuals.health.mil/pages/DisplayManualHtmlFile/2025-08-12/AsOf/tpt5/c7s1_2.html</urlRef>
        <urlRef>https://opa.hhs.gov/about/mission</urlRef>
        <urlRef>https://opa.hhs.gov/sites/default/files/2025-11/gender-dysphoria-report.pdf</urlRef>
        <urlRef>https://palveluvalikoima.fi/documents/1237350/22895008/Summary_minors_en+</urlRef>
        <urlRef>https://policysearch.ama-assn.org/policyfinder/detail/%22Clarification%20of%20Evidence-Based%20Gender-Affirming%20Care%22?uri=%2FAMADoc%2FHOD-185.927.xml</urlRef>
        <urlRef>https://publications.aap.org/aapnews/news/19021/AAP-continues-to-support-care-of-transgender</urlRef>
        <urlRef>https://publications.aap.org/aapnews/news/25340/AAP-reaffirms-gender-affirming-care-policy</urlRef>
        <urlRef>https://segm.org/Finland_deviates_from_WPATH_prioritizing_psychotherapy_no_surgery_for_minors</urlRef>
        <urlRef>https://transhealthproject.org/resources/medical-organization-statements/</urlRef>
        <urlRef>https://tricare.triwest.com/globalassets/tricare/provider/TRICARE-West-Region-Gender-Dysphoria-PK.pdf</urlRef>
        <urlRef>https://ukom.no/rapporter/pasientsikkerhet-for-barn-og-unge-med-kjonnsinkongruens/sammendrag</urlRef>
        <urlRef>https://worldpopulationreview.com/state-rankings/age-of-majority-by-state</urlRef>
        <urlRef>https://www.aamc.org/news/states-are-banning-gender-affirming-care-minors-what-does-mean-patients-and-providers</urlRef>
        <urlRef>https://www.aha.org/system/files/2018-02/info-teaching.pdf</urlRef>
        <urlRef>https://www.apa.org/news/press/releases/2024/02/policy-supporting-transgender-nonbinary</urlRef>
        <urlRef>https://www.apa.org/topics/lgbtq/gender-affirmative-care</urlRef>
        <urlRef>https://www.batimes.com.ar/news/latin-america/brazil-prohibits-hormone-therapy-for-transgender-minors.phtml</urlRef>
        <urlRef>https://www.bls.gov/oes/tables.htm</urlRef>
        <urlRef>https://www.cms.gov/files/document/letter-stm.pdf</urlRef>
        <urlRef>https://www.cms.gov/priorities/innovation/key-concepts/quality-care</urlRef>
        <urlRef>https://www.england.nhs.uk/long-read/children-and-young-peoples-gender-services-implementing-the-cass-review-recommendations/</urlRef>
        <urlRef>https://www.england.nhs.uk/long-read/clinical-policy-prescribing-of-masculinising-and-feminising-hormones-for-children-and-adolescents-who-have-gender-incongruence-or-dysphoria-public-consultation-guide/</urlRef>
        <urlRef>https://www.govinfo.gov/content/pkg/FR-2025-01-30/pdf/2025-02090.pdf</urlRef>
        <urlRef>https://www.hhs.gov/press-room/gender-dysphoria-report-release.html</urlRef>
        <urlRef>https://www.hhs.gov/press-room/hhs-releases-peer-reviewed-report-discrediting-pediatric-sex-rejecting-procedures.html</urlRef>
        <urlRef>https://www.kff.org/other/dashboard/gender-affirming-care-policy-tracker</urlRef>
        <urlRef>https://www.lgbtmap.org/equality-maps/healthcare/youth_medical_care_bans</urlRef>
        <urlRef>https://www.medicaid.gov/federal-policy-guidance/downloads/sho24005.pdf</urlRef>
        <urlRef>https://www.medicaid.gov/medicaid/benefits/behavioral-health-services/children-and-youth</urlRef>
        <urlRef>https://www.medicaid.gov/medicaid/benefits/downloads/epsdt-coverage-guide.pdf</urlRef>
        <urlRef>https://www.medicaid.gov/sites/default/files/2019-12/epsdt_coverage_guide.pdf</urlRef>
        <urlRef>https://www.nejm.org/doi/full/10.1056/NEJMcp0800459</urlRef>
        <urlRef>https://www.nejm.org/doi/full/10.1056/NEJMoa2206297</urlRef>
        <urlRef>https://www.opm.gov/healthcare-insurance/carriers/fehb/2025/2025-01b.pdf</urlRef>
        <urlRef>https://www.opm.gov/healthcare-insurance/carriers/fehb/2025/2025-1a.pdf</urlRef>
        <urlRef>https://www.plasticsurgery.org/documents/health-policy/positions/2026-gender-surgery-children-adolescents.pdf</urlRef>
        <urlRef>https://www.reginfo.gov/public/pdf/eo14192/Accounting_Methods_under_EO_14192.pdf</urlRef>
        <urlRef>https://www.reuters.com/business/healthcare-pharmaceuticals/italy-moves-tighten-controls-gender-affirming-medical-care-minors-2025-08-05/</urlRef>
        <urlRef>https://www.reuters.com/investigates/special-report/usa-transyouth-data/</urlRef>
        <urlRef>https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/kunskapsstod/2022-12-8302.pdf</urlRef>
        <urlRef>https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/kunskapsstod/2023-1-8330.pdf</urlRef>
        <urlRef>https://www.statnews.com/2026/02/05/hospitals-stop-gender-care-minors-trump-administration-pressure/</urlRef>
        <urlRef>https://www.theguardian.com/australia-news/2025/jan/28/queensland-halts-prescription-of-puberty-blockers-and-hormones-for-children-with-gender-dysphoria</urlRef>
        <urlRef>https://www.theguardian.com/world/2025/nov/19/new-zealand-bans-new-prescriptions-of-puberty-blockers-for-young-transgender-people</urlRef>
        <urlRef>https://www.whitehouse.gov/wp-content/uploads/2025/08/CircularA-4.pdf</urlRef>
        <urlRef>regulations.gov</urlRef>
        <urlRef>www.cms.gov/files/document/hospital-oversight-letter-generic.pdf</urlRef>
    </extension>
    <relatedItem type="host" ID="P0b002ee1e6b1d555" xlink:href="https://www.govinfo.gov/metadata/pkg/FR-2026-08-13/mods.xml">
        <titleInfo>
            <title>Federal Register</title>
            <partNumber>Vol. 91, no. 155</partNumber>
        </titleInfo>
        <originInfo>
            <publisher>Office of the Federal Register, National Archives and Records Administration</publisher>
            <dateIssued encoding="w3cdtf">2026-08-13</dateIssued>
            <issuance>continuing</issuance>
            <frequency>daily</frequency>
        </originInfo>
        <physicalDescription>
            <note type="source content type">deposited</note>
            <digitalOrigin>born digital</digitalOrigin>
            <extent>264 p.</extent>
        </physicalDescription>
        <tableOfContents xlink:href="https://www.govinfo.gov/app/frtoc/2026-08-13">    
		  Table of Contents: 
		</tableOfContents>
        <classification authority="sudocs">AE 2.7:</classification>
        <classification authority="sudocs">GS 4.107:</classification>
        <classification authority="sudocs">AE 2.106:</classification>
        <classification authority="lcc">KF70.A2</classification>
        <identifier type="uri">https://www.govinfo.gov/app/details/FR-2026-08-13</identifier>
        <identifier type="local">P0b002ee1e6b1d555</identifier>
        <identifier type="issn">0097-6326</identifier>
        <identifier type="issn">0042-1219</identifier>
        <identifier type="issn">0364-1406</identifier>
        <identifier type="stock number">769-004-00000-9</identifier>
        <identifier type="ILS system id">000582072</identifier>
        <identifier type="former identifier">f:fr13au26</identifier>
        <location>
            <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/FR-2026-08-13</url>
            <url displayLabel="PDF rendition" access="raw object">https://www.govinfo.gov/content/pkg/FR-2026-08-13/pdf/FR-2026-08-13.pdf</url>
            <url displayLabel="XML rendition" access="raw object">https://www.govinfo.gov/content/pkg/FR-2026-08-13/xml/FR-2026-08-13.xml</url>
        </location>
        <accessCondition type="GPO scope determination">fdlp</accessCondition>
        <part type="issue">
            <extent unit="pages">
                <start>52219</start>
                <end>52474</end>
            </extent>
        </part>
        <recordInfo>
            <recordContentSource authority="marcorg">DGPO</recordContentSource>
            <recordCreationDate encoding="w3cdtf">2026-08-13</recordCreationDate>
            <recordChangeDate encoding="w3cdtf">2026-08-13</recordChangeDate>
            <recordIdentifier source="DGPO">FR-2026-08-13</recordIdentifier>
            <recordOrigin>machine generated</recordOrigin>
            <languageOfCataloging>
                <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
            </languageOfCataloging>
        </recordInfo>
        <extension>
            <docClass>FR</docClass>
            <accessId>FR-2026-08-13</accessId>
            <volume>91</volume>
            <issue>155</issue>
        </extension>
    </relatedItem>
</mods>
